Bissonnette Luc, Bergeron Michel G
Département de Biologie Médicale (Microbiologie), Faculté de Médecine, Université Laval, Québec City, Canada.
Expert Rev Mol Diagn. 2006 May;6(3):433-50. doi: 10.1586/14737159.6.3.433.
The molecular diagnosis of infectious diseases is currently going through a revolution sustained by the regulatory approval of amplification tests that have been shown to be equivalent or superior to existing gold standard methods. The recent approval of a microarray system for the pharmacogenomic profiling of cytochrome P450-mediated drug metabolism is paving the way to novel, rapid, sensitive, robust and economical microfabricated systems for point-of-care diagnostics, which are utilized closer and closer to the patient's bedside. These systems will enable the multiparametric genetic evaluation of several medical conditions, including infectious diseases. This forecoming revolution will position molecular theranostics in a broader integrated view of personalized medicine, which exploits genetic information from microbes and human hosts to optimize patient management and disease treatment.
传染病的分子诊断目前正经历一场变革，这一变革由扩增检测的监管批准所推动，这些检测已被证明等同于或优于现有的金标准方法。最近，一种用于细胞色素P450介导的药物代谢的药物基因组学分析的微阵列系统获得批准，这为用于即时诊断的新型、快速、灵敏、稳健且经济的微制造系统铺平了道路，这些系统越来越靠近患者床边使用。这些系统将能够对包括传染病在内的多种医疗状况进行多参数基因评估。这场即将到来的变革将把分子治疗诊断学置于个性化医疗的更广泛综合视野中，该视野利用来自微生物和人类宿主的遗传信息来优化患者管理和疾病治疗。
